LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX), a niche specialty pharmaceutical company, today provided full year 2012 financial guidance. The Company’s guidance includes the expected impact of the recent product acquisition from H. Lundbeck A/S, but excludes any impact of the pending acquisition of certain assets from Kilitch Drugs (India) Limited, as well as the impact from any products for which the company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2011 conference call.
